Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Policy Options for Contributory Health Insurance Schemes in Low and Lower-Middle Income Countries to Enable Progress Towards Universal Health Coverage.
Health Syst Reform
December 2024
Results for Development, USA.
The promise of contributory health insurance to generate additional, self-sustaining funding for the health sector has not been achieved in many low- and lower-middle-income countries. Instead, contributory health insurance has been found to exacerbate inequities in access to health care because entitlements are linked to contributions. For these countries with contributory health insurance schemes, with separate institutional arrangements for revenue collection and purchasing, that operate alongside budget-funded and other health financing schemes, it is usually not politically or technically feasible to reverse or eliminate these arrangements even when they fragment the health system.
View Article and Find Full Text PDFPricing for Multi-Indication Drugs in the Italian Regulatory Context.
Pharmacoecon Open
January 2025
HTA & Pharmaceutical Economics Department, Italian Medicines Agency (AIFA), Rome, Italy.
Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount attributed to the extension of indications (EoIs) to explore the potential correlation between spending and negotiated discounts and to find specific factors (determinants) that impact on discount.
Methods: The study focused on drugs approved in Italy between 2003 and 2017 with at least four therapeutic indications, including the first approved and EoIs, with follow-up extended until 2021 to acquire all the information on the negotiation process that has been completed.
A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced breast cancer.
Breast Cancer Res Treat
January 2025
Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Purpose: Understanding real-world treatment patterns and their effectiveness in HR + HER2- advanced breast cancer (aBC) in Canadian patients.
Patient And Methods: This was a multi-center, observational, prospective cohort study including men and pre-/peri-/postmenopausal women with HR + HER2- aBC receiving endocrine therapy (ET) or ET + targeted therapy (ET + TT). The primary objective was duration of treatment (DOT) with ET and ET + TT.
Cystectomy for bilateral thigh fistulation after salvage radiotherapy for prostate cancer: A case report.
Urol Case Rep
November 2024
Fiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA, 6150, Australia.
Fistulation following radiotherapy for prostate cancer is a rare occurrence that can have devastating consequences and often occurs after instrumentation. We present a 74-year-old male who underwent cystectomy for bilateral thigh fistulation years after radical prostatectomy and salvage radiotherapy for prostate cancer. MRI and CT cystogram confirmed fistulation from the anterior bladder tracking to bilateral thigh collections.
View Article and Find Full Text PDFMarital status shows no protective effect on perioperative outcomes after robotic-assisted pulmonary lobectomy.
Surg Pract Sci
September 2024
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Background: Marital status has been shown to have protective effects for married patients with various cancers. We sought to determine effects of marital status on perioperative outcomes after robotic-assisted pulmonary lobectomy (RAPL).
Methods: We retrospectively analyzed 709 consecutive patients who underwent RAPL between 2010 and 2022 by one surgeon.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!